Skip to NavigationSkip to content

Roche's subcutaneous Perjeta/Herceptin combo proves non-inferior to IV formulation in HER2-positive early breast cancer

Published on 12/12/19 at 01:05pm

New Phase 3 data from Roche has shown that its subcutaneously-delivered formulation of Perjeta (pertuzumab) and Herceptin (trastuzumab), in combination with intravenous (IV) chemotherapy, proved non-inferior to its standard IV infusion formulation in the treatment of HER2-positive early breast cancer (eBC).

Specifically, the subcutaneous formulation met its primary endpoint, showing non-inferior levels of Perjeta in the blood in addition to comparable efficacy and safety to the standard IV infusion.

On top of this, the subcutaneous version is much faster to administer, requiring eight minutes for the initial loading dose and around five minutes for each subsequent dose. Conversely, the IV infusion takes around 150 minutes to administer a loading dose, with subsequent doses requiring anywhere between 60 and 150 minutes.

These advantages are taken alongside the preference expressed for subcutaneous delivery by patients in previous studies, principally because of its shorter duration.

“This fixed-dose subcutaneous combination has the potential to provide a quicker and less invasive method of administration for people with HER2-positive breast cancer being treated with Perjeta and Herceptin,” remarked Dr Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development. “This is the first time that we have brought together two of our targeted antibodies as a single subcutaneous injection that can be administered in just minutes.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches